Breast Cancer: PACCT-1 (Hematology Oncology Associates)

Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment

Objective

This study is for patients with breast cancer that is estrogen receptor and/or progesterone receptor positive that has not spread to the axillary lymph nodes.

The purpose of this study is to determine whether patients who have a tumor with an Oncotype DX Recurrence Score of 11-25 benefit from chemotherapy, and to confirm that patients who have Oncotype DX Recurrence Score of < 10 have a very low risk of recurrence with hormonal therapy alone (and do not need chemotherapy to reduce their risk of recurrence).

Another objective is to create a tissue and blood specimen bank that includes specimens from all women who participate in this study, and to collect follow-up information regarding the health status of all women who participate in the study. This will allow researchers to evaluate new diagnostic tests in the future as they develop that may predict benefit or side effects from certain treatments.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
Cancer Trials Support Unit
Contact
Katy D'Aprile, RN, BSN at 563-355-7733

Location

  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email